Tau radiotracers for Baltimore Longitudinal Study of Aging
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH NIDA
National Institutes of Health is planning to buy "Tau radiotracers for Baltimore Longitudinal Study of Aging". This is an early notice: it is not taking bids yet. The work is in USA. Responses are due Oct 27, 2026. In the last 2 years, similar work went to 3 companies, usually for about $137K per award. An award is expected between December 2026 and August 2027.
Put together from the facts on this page; the details and sources are below.
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75N98027Q00029 in this department, oldest first.
- Oct 22, 2026 · this noticeSources Sought
- Oct 22, 2026Sources SoughtView
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
SAM.gov SOURCES SOUGHT NOTICE Solicitation Number: 75N98027Q00029 Title: Tau radiotracers for Baltimore Longitudinal Study of Aging Classification Code: 6505 NAICS Code: 325414 Description: Biological Product (except Diagnostic) Manufacturing This is a Small Business Sources Sought Notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned… (show all)
small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: The BLSA was initiated in 1958 and is a multi-disciplinary study of physiologic and psychologic aspects of normal aging in community-dwelling men and women. Since 1994, we have been conducting a longitudinal brain imaging study of selected older adults in the BLSA to characterize individual differences in longitudinal brain changes, to investigate the extent to which these brain changes underlie individual differences in cognitive aging, to identify brain changes that may be predictors of cognitive decline and Alzheimer�s disease (AD), and to assess the impact of potential modulators of brain and cognitive aging. More recently, we have been collecting in vivo measures of brain amyloid and tau, the hallmark pathologies of AD, using PET scanning. The purpose of this acquisition is to acquire FDA- approved second generation tau PET imaging radioligand to perform in vivo Positron Emission Tomography (PET) scans to measure brain tau neuropathology in BLSA participants on a combined PET/computed tomography (CT) scanner. Purpose and Objectives: The purpose of this acquisition is to procure Tau radiotracers for the Baltimore Longitudinal Study of Aging. Project requirements: Independently, and not as an agent of the Government, the Contractor shall provide the following: 95 Tau radioligand doses for the base period. 95 Tau radioligand doses for option period 1. 95 Tau radioligand doses for option period 2. Anticipated period of performance: Base Year: November 18, 2026 � November 17, 2027 Option Year 1: November 18, 2027 � November 17, 2028 Option Year 2: November 18, 2028 � November 17, 2029 Requested Response: The intent of this sources sought notice is to define the procurement strategy (e.g. set-aside, sole source, unrestricted) for a solicitation that is intended to be posted soon. Interested contractors are requested to respond by (1) identifying how their proposed product meets or exceeds the project requirements listed above; and (2) providing product literature, white papers, or capability statements that demonstrate their bona fide ability to supply such an item within the time frame described above. In addition, please state your business size status and whether you are the manufacturer or authorized distributor of the item you propose. Please note that NIH is particularly interested in small business sources. If you are a small business, please state the type of small business (small business; HUBZone; service-disabled, veteran-owned; 8(a); veteran-owned; woman-owned; or small disadvantaged businesses) and your size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. The information submitted must be must be in an outline format that addresses each of the elements of the project requirements and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response must include the respondents� technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Kevin Alvarez, Contracting Officer, at e-mail address kevin.alvarez@nih.gov. The response must be received on or before October 27, 2026, 9:00am, Eastern Time. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published at SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
Who won similar work
3 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same product/service code (PSC) 6505.
Single-winner award sizes (3): middle half $82K to $470K, median $137K; range $28K to $804K.
| Winner | Awards | Value | Last |
|---|---|---|---|
| VECTOR BIOMED INC. | 1 | $804K | Dec 2, 2024 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC · $PACB · $159.3M | 1 | $137K | Nov 19, 2024 |
| 10X GENOMICS, INC. · $TXG · $616.9M | 1 | $28K | Dec 20, 2024 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
- $PACB reported $159.3M revenue (12 months to Jun 30, 2026). The median single-winner award in these 3 past awards, $137K, is under 0.1% of that. SEC filing
- $TXG reported $616.9M revenue (12 months to Jun 30, 2026). The median single-winner award in these 3 past awards, $137K, is under 0.1% of that. SEC filing
One award's total value against one year of revenue; many awards are paid over several years.
- Dec 20, 202410X GENOMICS, INC.$28K65--Xenium Add On KitMateriality: <0.01% of $TXG revenue (Low) SEC
- Dec 2, 2024VECTOR BIOMED INC.$804KServices for the Production and Stability Testing of Clinical Grade Lentiviral VectorNo listed company matched (Materiality N/A)
- Nov 19, 2024PACIFIC BIOSCIENCES OF CALIFORNIA, INC$137K65--Revio SPRQ reagent kitMateriality: 0.09% of $PACB revenue (Low) SEC
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 3 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 2 of the past winners are listed companies
- 0 insider buys and 5 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.